
Rienk Offringa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/626995/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	T cell-mediated elimination of cancer cells by blocking CEACAM6–CEACAM1 interaction. Oncolmmunology, 2022, 11, 2008110.	4.6	14
2	p38 MAPK signaling in M1 macrophages results in selective elimination of M2 macrophages by MEK inhibition. , 2021, 9, e002319.		19
3	Timed Ang2-Targeted Therapy Identifies the Angiopoietin–Tie Pathway as Key Regulator of Fatal Lymphogenous Metastasis. Cancer Discovery, 2021, 11, 424-445.	9.4	18
4	Photon versus carbon ion irradiation: immunomodulatory effects exerted on murine tumor cell lines. Scientific Reports, 2020, 10, 21517.	3.3	13
5	Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy. Nature Communications, 2020, 11, 2176.	12.8	43
6	Phosphoproteomics of CD2 signaling reveals AMPK-dependent regulation of lytic granule polarization in cytotoxic T cells. Science Signaling, 2020, 13, .	3.6	18
7	The m6A-Related mRNA Signature Predicts the Prognosis of Pancreatic Cancer Patients. Molecular Therapy - Oncolytics, 2020, 17, 460-470.	4.4	35
8	Novel Non-integrating DNA Nano-S/MAR Vectors Restore Gene Function in Isogenic Patient-Derived Pancreatic Tumor Models. Molecular Therapy - Methods and Clinical Development, 2020, 17, 957-968.	4.1	15
9	Radiation-induced alterations in immunogenicity of a murine pancreatic ductal adenocarcinoma cell line. Scientific Reports, 2020, 10, 686.	3.3	11
10	The Outcome of <i>Ex Vivo</i> TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic <i>In Vitro</i> Growth Capacity between T-Cell Clones. Clinical Cancer Research, 2020, 26, 4289-4301.	7.0	46
11	Targeting immune-checkpoint inhibitor resistance mechanisms by MEK inhibitor and agonist anti-CD40 antibody combination therapy. Cell Stress, 2020, 4, 248-251.	3.2	3
12	Sensitization of Tumors for Attack by Virus-Specific CD8+ T-Cells Through Antibody-Mediated Delivery of Immunogenic T-Cell Epitopes. Frontiers in Immunology, 2019, 10, 1962.	4.8	31
13	Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display. Frontiers in Immunology, 2019, 10, 2766.	4.8	23
14	Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models. Oncolmmunology, 2018, 7, e1445457.	4.6	13
15	Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. Oncolmmunology, 2017, 6, e1371896.	4.6	36
16	Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. Oncolmmunology, 2016, 5, e1240859.	4.6	75
17	Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients. Carcinogenesis, 2016, 37, 957-964.	2.8	14
18	Next-generation TCR sequencingÂ-Âa tool to understand T-cell infiltration in human cancers. Journal of Pathology, 2016, 240, 384-386.	4.5	25

RIENK OFFRINGA

#	Article	IF	CITATIONS
19	A highâ€throughput <scp>RNA</scp> i screen for detection of immuneâ€checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes. EMBO Molecular Medicine, 2015, 7, 450-463.	6.9	39
20	Cancer immunotherapy: exploiting neoepitopes. Cell Research, 2015, 25, 887-888.	12.0	25
21	Development of Next-Generation Immunomodulatory Antibodies for Cancer Therapy through Optimization of the IgG Framework. Cancer Cell, 2015, 28, 273-275.	16.8	16
22	Prevailing Role of Contact Guidance in Intrastromal T-cell Trapping in Human Pancreatic Cancer. Clinical Cancer Research, 2014, 20, 3422-3433.	7.0	158
23	An FcÎ ³ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling inÂCancer Cells. Cancer Cell, 2011, 19, 101-113.	16.8	247
24	Antigen choice in adoptive T-cell therapy of cancer. Current Opinion in Immunology, 2009, 21, 190-199.	5.5	41
25	Self-Tolerance Does Not Restrict the CD4+ T-Helper Response against the p53 Tumor Antigen. Cancer Research, 2008, 68, 893-900.	0.9	50
26	Association of cervical cancer with the presence of CD4 ⁺ regulatory T cells specific for human papillomavirus antigens. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12087-12092.	7.1	201